𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: A systematic review of evidence

✍ Scribed by Brent C. Taylor; Jian-Min Yuan; Tatyana A. Shamliyan; Aasma Shaukat; Robert L. Kane; Timothy J. Wilt


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
150 KB
Volume
49
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


We systematically reviewed the literature on the extent to which population characteristics or clinical features predict groups of individuals likely to develop advanced liver disease or die from chronic infection with hepatitis B virus (HBV). We searched Medline to include studies with reported cirrhosis, liver failure, liver cancer, or death outcomes after at least 1 year of follow-up from the measurement of predictive factors (age, age at infection, geographic location, race/ ethnicity, sex, positive family history, presence of coinfections, HBV viral level, change in hepatitis B e antigen [HBeAg] status, genotype, HBV mutations, nonalcoholic fatty liver disease, alcohol consumption, liver enzymes, and liver biopsy finding). Evidence from 41 included articles suggested that cirrhosis, higher HBV viral level, and male sex were consistently associated with significantly increased risk of death and liver cancer. Evidence about the role of HBV genotype, HBeAg status, age and duration of infection, coinfections with hepatitis C virus, human immunodeficiency virus, hepatitis delta virus, and alanine aminotransferase levels were limited and inconsistent, but were deemed promising to identify patients at higher risk of clinical outcomes. Adults with chronic hepatitis B had increased risk for poorer health outcomes compared to the general population; however, the magnitude of risk varied greatly depending on baseline patient and disease characteristics, and typically clinical outcomes required many years to become manifest. Many adults with chronic hepatitis B had low absolute risks of clinical outcomes and likely would not benefit from immediate treatment. Baseline patient and disease characteristics provide important information about the risk of clinical outcomes and should be incorporated into monitoring or treatment decisions. (HEPATOLOGY 2009;49:S85-S95.)

Methods

We searched Medline up to June 2008 using the search string found in Table 1, and also hand-searched and evaluated articles suggested by our Technical Expert Panel. In


πŸ“œ SIMILAR VOLUMES


Clinical utility of hepatitis B surface
✍ Yun-Fan Liaw πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 162 KB πŸ‘ 2 views

This clinically relevant review focuses on recent findings concerning hepatitis B surface antigen (HBsAg) quantitation in untreated patients and treated patients with chronic hepatitis B. Recent studies and emerging data have shown that both HBsAg and hepatitis B virus (HBV) DNA levels decline durin

Clinical utility of hepatitis B surface
✍ Yun-Fan Liaw πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 164 KB πŸ‘ 2 views

This clinically relevant review focuses on recent findings concerning hepatitis B surface antigen (HBsAg) quantitation in untreated patients and treated patients with chronic hepatitis B. Recent studies and emerging data have shown that both HBsAg and hepatitis B virus (HBV) DNA levels decline durin

Correction: β€œClinical utility of hepatit
πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 45 KB πŸ‘ 1 views

In the June 2011 issue of HEPATOLOGY, in the article entitled ''Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review'' (volume 53, pages 2121-2129) the data in Tables 2 and3 are to be corrected as listed below: On page 2124, under the heading '

Evidence for a deficiency of interferon
✍ Tadashi Ikeda; Andrew M. L. Lever; Professor Howard C. Thomas πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 406 KB πŸ‘ 2 views

Ninety per cent of patients infected in adult life with the hepatitis B virus clear the virus completely and 10% develop chronic infection. There is evidence for the involvement of interferon in the clearance of acute hepatitis B virus infection. We report that, in in vitro tests, some hepatitis B v

Diagnosis and clinical impact of occult
✍ Sagnelli Evangelista; Imparato Michele; Coppola Nicola; Pisapia Raffaella; Sagne πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 88 KB πŸ‘ 2 views

## Abstract Occult hepatitis B virus (HBV) infection in patients with chronic hepatitis C has been found associated with severe liver damage, low response to interferon treatment and increased risk of developing HCC. However, doubts remain on its clinical impact and the sensitivity and specificity

Systematic review and meta-analysis of i
✍ S. Breitenstein; D. Dimitroulis; H. Petrowsky; M. A. Puhan; B. MΓΌllhaupt; P.-A. πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 2 views

## Abstract ## Background A combined antiviral and tumoricidal effect of interferon (IFN) is assumed to occur after resection or ablation of hepatocellular carcinoma (HCC). ## Methods An electronic search of the Medline, Embase and Central databases from January 1998 to October 2007 was conducte